On June 30, Liquidia Technologies rose 5.07% in regular trading, trading at approximately $79.13 per share, with turnover of $34.12 million.

On the news front, the stock is rebounding after BofA Securities downgraded Liquidia from Buy to Neutral with a $79 price target the prior trading day, which triggered profit-taking and pushed shares down over 5% to around $73. The current recovery brings the stock back near the analyst target price level, suggesting the market has largely digested the rating adjustment.

Fundamentally, the company reported Q1 EPS of $0.52, beating the consensus estimate of $0.41 by approximately 27%. Core product YUTREPIA generated net product sales of approximately $130 million, with over 4,500 unique patient prescriptions, representing a swing to profitability year-over-year. The company also announced poster presentations at the PHA International PH Conference, providing additional catalysts. Despite the strong underlying performance, the downgrade suggests current valuation may fully reflect near-term positives.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)